Mr. Thomas Smeenk reports

HEMOSTEMIX SELLS ITS 23RD ACP-01 THERAPY CONVERTIBLE DEBENTURE

Hemostemix Inc. has sold 15 ACP-01 therapy convertible debentures for proceeds of $517,230 (U.S.), subject to the approval of the TSX Venture Exchange.

"Year to date, this sums to forward sales of $1,149,983, which is gratifying, as it generates non-dilutive working capital for our company and its shareholders," stated Thomas Smeenk, chief executive officer. "Importantly, forward sales enable the scheduling of both production and physician time in a very orderly manner. Moreover, forward sales generate a ramp-up of production from 20 to 40 treatments per month and from 40 to 80 treatments per month from revenue. Given 20 treatments per month generate annual revenue of $8.88-million (U.S.) ($12,876,000); given one physician completing four blood draws per day generates 80 treatments per month (four multiplied by $8.88-million (U.S.)); shareholders can quickly understand how we scale operations to our run rate as we announce additional forward sales and agreements with clinics and clinicians globally," Mr. Smeenk stated.

An unsecured obligation of Hemostemix, each ACP-01 therapy convertible debenture (TCD) is convertible into an ACP-01 therapy on a first-purchased basis. Transferable, saleable subject to a Hemostemix ROFR (right of first refusal), willable and convertible into equity at the option of the purchaser, each TCD collects interest at 6 per cent per annum payable annually in shares of Hemostemix at the average closing price per share for the 10 days preceding Dec. 31 of each year. TCDs may be listed to trade on a stock exchange at a date in the future.

About Hemostemix Inc.

Hemostemix is an autologous stem cell therapy company founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the company has developed, patented, is scaling and is selling autologous (patient's own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01), and later neural cell precursors (NCP-01), and cardiomyocyte cell precursors (CCP-01). Hemostemix has treated 498 patients, completed seven clinical studies of 318 subjects and published its results in nine peer-reviewed publications. ACP-01 is safe, clinically relevant and statistically significant treatment for peripheral arterial disease, chronic limb-threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure and angina. Hemostemix completed its phase II clinical trial for chronic limb-threatening ischemia.

We seek Safe Harbor.